Atlanta-A trial of drug regimens in hormone-refractory prostate cancer came up with only modest results, but it did take an important first step: It is one of the first prospective trials conducted in taxane-refractory disease.
Pivotal data for lumasiran in PH1 published in NEJM
The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug.
Nedosiran explored in primary hyperoxaluria type 3
The RNAi drug nedosiran is a once-monthly subcutaneous injection under investigation for all 3 types of primary hyperoxaluria.
Enrollment completed in pivotal trial of nedosiran for hyperoxaluria
FDA new drug application filing expected by the end of 2021.
FDA approves androgen inhibitor for metastatic PCa
The FDA recently approved the oral androgen receptor inhibitor enzalutamide (Xtandi) for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel (Taxotere).
Blood test could guide treatment for kidney cancer
A common enzyme that is easily detected in blood may predict how well patients with advanced kidney cancer will respond to a specific treatment, according to physicians at Duke Cancer Institute, Durham, NC.
BCG for bladder cancer in short supply
Due to manufacturing issues, a formulation of the bladder cancer treatment bacillus Calmette-GuÃ©rin is currently unavailable from one manufacturer.
2 Clarke Drive Cranbury, NJ 08512